← DeepTechTracker
Individual portraits of Kartik Sunagar and Vinay Prabhu, arranged side by side with names

Venomics AI raises $2.7M to search animal venoms for medicines

Kartik Sunagar, co-founder/director (left), and Vinay Prabhu, co-founder/CTO (right). Individual photos: Venomics AI; layout: DTT.

Venomics AI has raised $2.7 million in a pre-seed round co-led by Speciale Invest and South Park Commons, with participation from Operators Studio. The IISc spinout combines venom biology, artificial intelligence and laboratory screening to look for molecules that could become medicines.

Public coverage appeared in November. The company’s own timeline dates the same $2.7 million funding milestone to 10 April 2026. The legal closing date is not independently confirmed; this should not be read as a newly closed November round.

Venoms contain peptides, small chains of amino acids that can act on specific targets in the body. Venomics is building a Venom Atlas that links molecular information to measurements from its laboratory. AI models help rank promising candidates, while experiments check whether the predictions hold up.

The funding will expand the Atlas, AI and laboratory screening capabilities, and the team across venom biology, computational science and drug discovery. It will also support validation and improvement of promising molecules. South Park Commons identifies antimicrobial resistance, infections that no longer respond to antibiotics, as an initial target.

Co-founders Kartik Sunagar and Vinay Prabhu bring venom research and AI expertise. Sunagar is a professor at IISc and leads its Evolutionary Venomics Lab. Prabhu is the company's chief technology officer.

These are early drug-discovery programmes, not approved medicines or demonstrated treatments in patients. AI predictions must survive laboratory tests and later development before they can become drugs.

Read at source ↗

DTT summary based on Venomics AI / Speciale Invest / South Park Commons's report. The full article is on the publisher's site.

Additional reporting

Browse more DeepTech news →

Who's raising. Who's funding. What's next in DeepTech.